scholarly journals A CASE OF BILE DUCT CANCER WITH LONG-TERM SURVIVAL AFTER OPERATION IN SPITE OF RESIDUAL CANCER AT THE RESECTED MARGIN

2000 ◽  
Vol 61 (2) ◽  
pp. 467-471 ◽  
Author(s):  
Shinichirou OHUCHI ◽  
Taiji SETO ◽  
Takao HANAOKA ◽  
Rikkou LEE ◽  
Yuichi TANAKA ◽  
...  
Keyword(s):  
Bile Duct ◽  
Bile Duct Cancer ◽  
Residual Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Duct Cancer ◽  
Resected Margin

Long-term survival of a patient with common bile duct cancer after Virchow’s node recurrence: Report of a case

Surgery Today ◽  
2011 ◽  
Vol 41 (10) ◽  
pp. 1432-1435
Author(s):  
Toshiya Ochiai ◽  
Hisashi Ikoma ◽  
Koji Inoue ◽  
Shuhei Komatsu ◽  
Yasutoshi Murayama ◽  
...  
Keyword(s):  
Bile Duct ◽  
Common Bile Duct ◽  
Bile Duct Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Common Bile Duct Cancer ◽  
Duct Cancer ◽  
Virchow’S Node

Could a high resectability rate improve the long-term survival of patients with proximal bile duct cancer?

2006 ◽  
Vol 93 (3) ◽  
pp. 199-205 ◽  
Author(s):  
Massimiliano Veroux ◽  
Carmelo Madia ◽  
Pietro Fiamingo ◽  
Pietro Caglià ◽  
Maurizio Valastro ◽  
...  
Keyword(s):  
Bile Duct ◽  
Bile Duct Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Resectability Rate ◽  
Duct Cancer ◽  
Proximal Bile Duct

Carcinoid of the Extra-Hepatic Bile Duct: A Case Report with Long-Term Follow-up and Review of Literature

2008 ◽  
Vol 74 (1) ◽  
pp. 87-90 ◽  
Author(s):  
Niraj J. Gusani ◽  
J. Wallis Marsh ◽  
Michael A. Nalesnik ◽  
Mitchell E. Tublin ◽  
T. Clark Gamblin
Keyword(s):  
Bile Duct ◽  
Carcinoid Tumor ◽  
Extrahepatic Bile Duct ◽  
Strong Support ◽  
Complete Excision ◽  
Term Survival ◽  
Long Term Survival ◽  
Long Term Follow Up

Extrahepatic bile duct tumors, 80 per cent of which are adenocarcinomas, are rare neoplasms accounting for less than two per cent of all cancers. Carcinoid tumor of the extrahepatic bile ducts is a reportable lesion, with only approximately 50 cases described in the literature since 1959. We present a case of a primary extrahepatic bile duct carcinoid tumor resected for cure with the longest reported follow-up time (11 years) after surgery. We also summarize the existing literature with regard to this rare tumor. Our case lends strong support to the notion that extrahepatic biliary carcinoids are generally indolent lesions that, if aggressively resected, can result in excellent long-term survival. Complete excision with clear margins seems to provide the best chance of obtaining long-term survival and cure.

scholarly journals Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel

2019 ◽  
Vol 27 (2) ◽  
Author(s):  
A. Surinach ◽  
T. Phung ◽  
O. Abdul-Rahim ◽  
M. Khushman
Keyword(s):  
Bile Duct ◽  
Karnofsky Performance Status ◽  
Stage Iv ◽  
Relative Survival ◽  
The United States ◽  
Ductal Adenocarcinoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Liposomal Irinotecan

At 9%, and 2% when diagnosed at advanced stage, the 5-year relative survival rate for pancreatic ductal adenocarcinoma (pdac) is the lowest of any cancer. The currently approved treatment options for metastatic pdac in the United States are folfirinox [irinotecan–fluorouracil (5fu)–leucovorin (lv)–oxaliplatin], gemcitabine–nab-paclitaxel, and liposomal irinotecan plus 5fu–lv. Liposomal irinotecan is a novel formulation of irinotecan encapsulated within a lipid bilayer, which favours localmetabolic activation. The napoli-1 trial demonstrated the efficacy of liposomal irinotecan in combination with 5fu and lv for the treatment of advanced pdac after progression on gemcitabine-based chemotherapy. The 1-year survival in those patients was 25%; however, none had had irinotecan-refractory disease before treatment with liposomal irinotecan. Furthermore, the U.S. National Comprehensive Cancer Network guidelines recommend liposomal irinotecan plus 5fu–lv in patients who have received prior fluoropyrimidine-based therapy if no prior irinotecan therapy has been given. Here, we report a male patient with stage iv cancer of pancreas or bile duct (site unconfirmed) who experienced a prolonged (51 weeks) response to liposomal irinotecan plus 5fu–lv despite prior disease progression on irinotecan. Several factors have previously been associated with long-term survival in patients receiving liposomal irinotecan therapy: no prior irinotecan-based chemotherapy, high Karnofsky performance status score, age 65 years or less, serum carbohydrate antigen 19-9 less than 59 U/mL, neutrophil-to-lymphocyte ratio 5 or less, and absence of liver metastasis. The patient in the present report had none of those characteristics indicative of long-term survival, except his age at diagnosis—47 years.

scholarly journals Actual Long-term Outcome of Extrahepatic Bile Duct Cancer After Surgical Resection

2005 ◽  
Vol 241 (1) ◽  
pp. 77-84 ◽  
Author(s):  
Jin-Young Jang ◽  
Sun-Whe Kim ◽  
Do Joong Park ◽  
Young Joon Ahn ◽  
Yoo-Seok Yoon ◽  
...  
Keyword(s):  
Bile Duct ◽  
Surgical Resection ◽  
Bile Duct Cancer ◽  
Extrahepatic Bile Duct ◽  
Term Outcome ◽  
Extrahepatic Bile Duct Cancer ◽  
Long Term Outcome ◽  
Duct Cancer
Sign in / Sign up

Export Citation Format

Share Document